Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 702 clinical trials
Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma

refractory T-cell acute lymphoblastic leukemia/lymphoma. 9-18 subjects will be enrolled. After the collection of PBMC and about 5 days before infusion, lymphodepletion (fludarabine at 30 mg/m^2/day and

  • 0 views
  • 10 Aug, 2022
  • 1 location
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia

This is a single arm, open-label, non-randomized, dose-escalation, phase I study to determine the safety and efficacy of CNCT19 in adult patients with relapsed or refractory acute lymphoblastic

  • 0 views
  • 17 Feb, 2021
  • 2 locations
Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation

/R) adult acute lymphoblastic leukemia bridging allogeneic hematopoietic stem cell transplantation.

  • 0 views
  • 26 Jan, 2021
  • 1 location
Venetoclax Based Regimen for R/R T-ALL

This study is to investigate the therapeutic efficacy and side effect of venetoclax based regimen for relapsed or refractroy T cell acute lymphoblastic leukemia.

  • 0 views
  • 15 Dec, 2021
  • 1 location
NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL

The purpose of this study is to determine the feasibility, safety, and efficacy of a combination therapy in the treatment of B-cell acute lymphoblastic leukemia (B-ALL) based on multi-antigen

  • 0 views
  • 13 Mar, 2022
  • 1 location
CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment

feeder T cells treatment for CD19+ acute lymphoblastic leukemia patients in remission .

  • 0 views
  • 08 Jun, 2022
  • 1 location
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.

  • 0 views
  • 09 Jul, 2022
  • 1 location
A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Lymphoma (B-ALL)

The researchers are doing this study to see if early reinfusion of tisagenlecleucel can keep participants in B-CEll ApLasia at 6 months after their first infusion. The researchers will also look at the safety of early reinfusion and how effective it is at treating B-ALL.

  • 0 views
  • 27 Jul, 2022
  • 1 location
Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL

Clinical Trial for the Safety and Efficacy of Sequential CD19 and CD22 CAR-T Therapy for Adult Patients With Newly Diagnosed Ph Chromosome Negative B-cell Acute Lymphoblastic Leukemia

  • 0 views
  • 12 Feb, 2021
  • 1 location
CAR-T Cell Therapy Targeting to CD19 for R/R ALL

Refractory and relapsed (R/R) acute lymphoblastic leukemia (ALL) patients with active disease always have a dismal outcome. Chimeric antigen receptor (CAR) T-cell therapy targeting to Cluster of

  • 0 views
  • 03 Feb, 2022
  • 1 location